Objective To explore the effect of polydatin on the proliferation and apoptosis of acute monocytic leukemia cell line THP-1 and the possible mechanism. Methods After THP-1 cells were treated with polydatin at gradient concentrations for 24 hours and 48 hours, their proliferation was determined by CCK-8 assay, and half maximal inhibitory concentration (IC50) was calculated. Logarithmically growing THP-1 cells were divided into two groups, a polydatin treatment group (treated with IC50 of polydatin) and a blank control group (treated without polydatin solution), and incubated for 48 hours. Cell apoptosis and cell cycle were measured by flow cytometry. The expression levels of PI3K, AKT, p-AKT, mTOR, p-mTOR, p70 S6K, and p-p70 S6K proteins were measured by Western blotting. Results After treatment with polydatin, the proliferation of THP-1 cells was strongly inhibited, and the IC50 at 48 hours was 1 800 μmol/L. After treatment with 1 800 μmol/L polydatin solution for 48 hours, the apoptosis rate of THP-1 cells increased significantly compared with the blank control group (P<0.05). The cell cycle was arrested in the G0/G1 and S phases, with a significantly increased proportion of cells in the G0/G1 phase and a significantly decreased proportion of cells in the S phase, as compared with the blank control group (P<0.05). The expression levels of PI3K, AKT, p-AKT, mTOR, p-mTOR, p70 S6K, and p-p70 S6K proteins decreased significantly compared with the blank control group (P<0.05). Conclusions Polydatin can effectively inhibit the proliferation, block the cell cycle, and induce the apoptosis of THP-1 cells, which may be related to inhibition of the PI3K/AKT/mTOR signaling pathway.
Key words
Leukemia /
Polydatin /
Cell proliferation /
Apoptosis /
THP-1 cell
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Wang Y, Mo H, Gu J, et al. Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway[J]. Exp Ther Med, 2017, 14(4): 3067-3073. PMID: 28912858. PMCID: PMC5585717. DOI: 10.3892/etm.2017.4855.
2 Liu LP, Zhang AL, Ruan M, et al. Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia[J]. Cancer Med, 2020, 9(11): 3647-3655. PMID: 32216042. PMCID: PMC7286455. DOI: 10.1002/cam4.3023.
3 Wang C, Luo Y, Lu J, et al. Polydatin induces apoptosis and inhibits growth of acute monocytic leukemia cells[J]. J Biochem Mol Toxicol, 2016, 30(4): 200-205. PMID: 26616494. DOI: 10.1002/jbt.21779.
4 Tan YY, Chen LX, Fang L, et al. Cardioprotective effects of polydatin against myocardial injury in diabetic rats via inhibition of NADPH oxidase and NF-κB activities[J]. BMC Complement Med Ther, 2020, 20(1): 378. PMID: 33308195. PMCID: PMC7733248. DOI: 10.1186/s12906-020-03177-y.
5 Tong Y, Wang K, Sheng S, et al. Polydatin ameliorates chemotherapy-induced cognitive impairment (chemobrain) by inhibiting oxidative stress, inflammatory response, and apoptosis in rats[J]. Biosci Biotechnol Biochem, 2020, 84(6): 1201-1210. PMID: 31992173. DOI: 10.1080/09168451.2020.1722057.
6 Zhang H, Chen Y, Pei Z, et al. Protective effects of polydatin against sulfur mustard-induced hepatic injury[J]. Toxicol Appl Pharmacol, 2019, 367: 1-11. PMID: 30677423. DOI: 10.1016/j.taap.2019.01.013.
7 Hanna DA, Khalaf MM, Abo-Saif AA. Polydatin protects against ovalbumin-induced bronchial asthma in rats; involvement of urocortin and surfactant-D expression[J]. Immunopharmacol Immunotoxicol, 2019, 41(3): 403-412. PMID: 30422021. DOI: 10.1080/08923973.2018.1536985.
8 Jiao Y, Wu Y, Du D. Polydatin inhibits cell proliferation, invasion and migration, and induces cell apoptosis in hepatocellular carcinoma[J]. Braz J Med Biol Res, 2018, 51(4): e6867. PMID: 29513792. PMCID: PMC5856444. DOI: 10.1590/1414-431X20176867.
9 Zou J, Yang Y, Yang Y, et al. Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway[J]. Biomed Pharmacother, 2018, 108: 130-136. PMID: 30218857. DOI: 10.1016/j.biopha.2018.09.051.
10 赵光辉, 宋晓旭, 刘宁, 等. PI3K/AKT/MTOR信号通路抑制剂在胃癌中的研究进展[J]. 癌症进展, 2019, 17(9): 1003-1007. DOI: 10.11877/j.issn.1672-1535.2019.17.09.04.
11 金娇悦, 苏丹. 肿瘤经典信号通路驱动基因变异与免疫检查点抑制剂疗效预测研究进展[J]. 中华病理学杂志, 2021, 50(7): 840-844. PMID: 34405632. DOI: 10.3760/cma.j.cn112151-20210120-00063.
12 Darici S, Alkhaldi H, Horne G, et al. Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence[J]. J Clin Med, 2020, 9(9): 2934. PMID: 32932888. PMCID: PMC7563273. DOI: 10.3390/jcm9092934.
13 Nepstad I, Hatfield KJ, Gr?nnings?ter IS, et al. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells[J]. Int J Mol Sci, 2020, 21(8): 2907. PMID: 32326335. PMCID: PMC7215987. DOI: 10.3390/ijms21082907.
PDF(913 KB)
